Anzeige
Mehr »
Login
Samstag, 04.05.2024 Börsentäglich über 12.000 News von 685 internationalen Medien
InnoCan Pharma: Multi-Milliarden-Wert in diesem Pennystock?!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
67 Leser
Artikel bewerten:
(0)

Acuo Technologies Announces Vendor Neutral Archiving Contract with CHRISTUS Health

BLOOMINGTON, Minn., Nov. 27, 2011 /PRNewswire/ --Acuo Technologies®, the leader in high-performance software and services for intelligent medical image lifecycle management and data migration, announced today that CHRISTUS Health has selected the Universal Clinical Platform (UCP3) as the company's new vendor neutral archive solution. UCP3 will replace CHRISTUS' existing PACS archives while providing an enterprise foundation for future on-premise and cloud-based clinical content management.

UCP3 will provide CHRISTUS Health with better access to all imaging data and a comprehensive solution for facility, partner and physician affiliation, while allowing the company to retire more expensive imaging archive systems across its facilities. UCP3 enables CHRISTUS to preserve its investment in existing PACS technology and storage assets, while providing an easier and more economical path for replacement of these systems when the time is right.

"We are pleased to be working with one of the country's largest and most respected integrated delivery networks," said Jeff Timbrook, CEO of Acuo Technologies. "It was clear during the evaluation process that CHRISTUS Health leaders, clinicians and technologists share Acuo's vision of the next generation of image management systems that are focused on delivering superior patient care while reducing costs throughout the enterprise."

"CHRISTUS Health partnered with Acuo Technologies after a thorough evaluation of the top VNA middleware suppliers," said George Conklin, CIO of CHRISTUS Health. "It was clear from the very start that Acuo's level of expertise in this type of technology was solid. Their team truly understands how to improve and simplify what has up until now been a very complex problem for health care providers. Their UCP3 product will give us the flexibility to deploy technology in a way that meets the needs of those we serve."

About Acuo Technologies

Acuo Technologies, with headquarters in Minneapolis/St. Paul, MN, was founded in 2000 with the objective of developing the first enterprise-wide collaborative Universal Clinical Platform (UCP3) solution for medical image content, both DICOM and Non-DICOM. Today, Acuo supports more than 675 implementations of UCP3 around the world. For more information on providing superior medical image lifecycle and content management while simplifying operations and reducing costs, visit www.acuotech.com.

About CHRISTUS HEALTH

CHRISTUS Health, an international Catholic, faith-based, not-for-profit health system, is headquartered in Dallas and is comprised of almost 350 services and facilities, including more than 50 hospitals and long-term care facilities, 175 clinics and outpatient centers and dozens of other health ministries and ventures. CHRISTUS services can be found in over 60 cities in Texas, Arkansas, Iowa, Louisiana, Missouri, New Mexico, Georgia and Mexico. The system employs approximately 30,000 Associates and has over 8,000 physicians on facility medical staffs who provide care and support for patients. CHRISTUS Health is listed among the top ten Catholic health systems in the U.S.

DICOM is the registered trademark of the National Electrical Manufacturers Association for its standards publications relating to digital communications of medical information.

SOURCE Acuo Technologies

Kupfer - Jetzt! So gelingt der Einstieg in den Rohstoff-Trend!
In diesem kostenfreien Report schaut sich Carsten Stork den Kupfer-Trend im Detail an und gibt konkrete Produkte zum Einstieg an die Hand.
Hier klicken
© 2011 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.